[ET Net News Agency, 19 April 2021] Nomura initiates coverage of Simcere Pharma
(02096) with a target price of HK$10.1 and a "buy" rating.
The research house said its valuation is based on 1.2x PEG (2021F PE/2021-23F CAGR),
slightly higher than the industry average (1.1x PEG) as it factors in an improving
pipeline portfolio and Simcere's national sales network. It estimates 2021-23F revenue/net
profit CAGR of 20%/22%, driven by sales growth for treatment in illnesses of the central
nervous system (CNS) and autoimmune deficiencies. (RC)